BR9711517A - Processo para reducÆo da resistencia a insulina em seres humanos nos quais a tolerancia a glicose enfraquecida ou o diabetes melito nÆo dependente de insulina nÆo se tenham apresentado da quantidade de insulina requerida diariamente por um ser humano que tenha diabetes melito e da resistencia a insulina em seres humanos para melhoria do peso e o controle do diabetes de pacientes de diabete melito nÆo dependente de insulina e para profilaxia e efeitos prejudiciais de longo prazo causados por alta - Google Patents

Processo para reducÆo da resistencia a insulina em seres humanos nos quais a tolerancia a glicose enfraquecida ou o diabetes melito nÆo dependente de insulina nÆo se tenham apresentado da quantidade de insulina requerida diariamente por um ser humano que tenha diabetes melito e da resistencia a insulina em seres humanos para melhoria do peso e o controle do diabetes de pacientes de diabete melito nÆo dependente de insulina e para profilaxia e efeitos prejudiciais de longo prazo causados por alta

Info

Publication number
BR9711517A
BR9711517A BR9711517A BR9711517A BR9711517A BR 9711517 A BR9711517 A BR 9711517A BR 9711517 A BR9711517 A BR 9711517A BR 9711517 A BR9711517 A BR 9711517A BR 9711517 A BR9711517 A BR 9711517A
Authority
BR
Brazil
Prior art keywords
insulin
diabetes mellitus
humans
dependent diabetes
insulin resistance
Prior art date
Application number
BR9711517A
Other languages
English (en)
Portuguese (pt)
Inventor
Robert Brian Jones
Helen Brian Jones
Clinfford James Bailey
Original Assignee
Knoll Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knoll Ag filed Critical Knoll Ag
Publication of BR9711517A publication Critical patent/BR9711517A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Electrotherapy Devices (AREA)
BR9711517A 1996-09-21 1997-09-15 Processo para reducÆo da resistencia a insulina em seres humanos nos quais a tolerancia a glicose enfraquecida ou o diabetes melito nÆo dependente de insulina nÆo se tenham apresentado da quantidade de insulina requerida diariamente por um ser humano que tenha diabetes melito e da resistencia a insulina em seres humanos para melhoria do peso e o controle do diabetes de pacientes de diabete melito nÆo dependente de insulina e para profilaxia e efeitos prejudiciais de longo prazo causados por alta BR9711517A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9619757.9A GB9619757D0 (en) 1996-09-21 1996-09-21 Chemical process
PCT/EP1997/005039 WO1998011884A1 (en) 1996-09-21 1997-09-15 Use of sibutramine analogues to prevent the development of diabetes

Publications (1)

Publication Number Publication Date
BR9711517A true BR9711517A (pt) 1999-08-24

Family

ID=10800326

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9711517A BR9711517A (pt) 1996-09-21 1997-09-15 Processo para reducÆo da resistencia a insulina em seres humanos nos quais a tolerancia a glicose enfraquecida ou o diabetes melito nÆo dependente de insulina nÆo se tenham apresentado da quantidade de insulina requerida diariamente por um ser humano que tenha diabetes melito e da resistencia a insulina em seres humanos para melhoria do peso e o controle do diabetes de pacientes de diabete melito nÆo dependente de insulina e para profilaxia e efeitos prejudiciais de longo prazo causados por alta

Country Status (26)

Country Link
US (3) US6174925B1 (https=)
EP (1) EP0927028A1 (https=)
JP (1) JP2001503737A (https=)
KR (1) KR20000048501A (https=)
CN (1) CN1237905A (https=)
AU (1) AU724488B2 (https=)
BG (1) BG64473B1 (https=)
BR (1) BR9711517A (https=)
CA (1) CA2266401C (https=)
CZ (1) CZ93699A3 (https=)
GB (1) GB9619757D0 (https=)
HR (1) HRP970505A2 (https=)
HU (1) HUP9904026A3 (https=)
ID (1) ID18320A (https=)
IL (1) IL128850A (https=)
MY (1) MY116150A (https=)
NO (1) NO991358D0 (https=)
NZ (1) NZ334580A (https=)
PL (1) PL332305A1 (https=)
RU (1) RU2245709C2 (https=)
SK (1) SK31999A3 (https=)
TR (1) TR199900618T2 (https=)
TW (1) TW580385B (https=)
UA (1) UA64726C2 (https=)
WO (1) WO1998011884A1 (https=)
ZA (1) ZA978450B (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process
WO2000000195A1 (en) * 1998-06-30 2000-01-06 Takeda Chemical Industries, Ltd. Pharmaceutical composition for the treatment of diabetes
JP2000080047A (ja) * 1998-06-30 2000-03-21 Takeda Chem Ind Ltd 医 薬
US6974838B2 (en) 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6476078B2 (en) * 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
HK1040910B (en) * 1998-11-12 2009-06-26 Smithkline Beecham Plc Pharmaceutical composition for modified release of an insulin sensitiser and metformin
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
AR023700A1 (es) * 1998-11-12 2002-09-04 Smithkline Beecham Plc Un procedimiento para preparar una composicion farmaceutica que comprende un sensibilizador de insulina
US6696495B2 (en) 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
US6323242B1 (en) 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
US6552087B1 (en) 1999-03-19 2003-04-22 Abbott Gmbh & Co. Kg Therapeutic agent comprising (+)-sibutramine
US6723717B1 (en) 1999-06-01 2004-04-20 The University Of Texas Southwestern Medical Center Sulfur-containing thyroxane derivatives and their use as hair growth promotors
CA2374260A1 (en) 1999-06-01 2000-12-07 The University Of Texas Southwestern Medical Center Method of treating hair loss using sulfonyl thyromimetic compounds
US6680344B1 (en) 1999-06-01 2004-01-20 The University Of Texas Southwestern Medical Center Method of treating hair loss using diphenylmethane derivatives
GB9914744D0 (en) * 1999-06-24 1999-08-25 Knoll Ag Therapeutic agents
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
US6610887B2 (en) 2001-04-13 2003-08-26 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
WO2003105809A1 (en) 2002-06-17 2003-12-24 Themis Laboratories Private Limited Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them
JP4278652B2 (ja) * 2002-10-05 2009-06-17 ハンミ ファーム． シーオー．， エルティーディー． 結晶性シブトラミンメタンスルホン酸塩半水和物を含む医薬組成物
US20050131074A1 (en) * 2003-08-04 2005-06-16 Beckman Kristen M. Methods for treating metabolic syndrome
PE20050335A1 (es) * 2003-08-07 2005-06-01 Sb Pharmco Inc Forma de dosificacion oral que comprende 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona y procedimiento para la preparacion
GB0318824D0 (en) * 2003-08-11 2003-09-10 Glaxo Group Ltd Novel composition
MXPA06004639A (es) * 2003-10-31 2006-06-27 Takeda Pharmaceutical Preparacion solida que comprende sensibilizador de insulina, secretagogo de insulina y ester de acidos grasos de polioxietileno sorbitano.
KR100627687B1 (ko) * 2005-04-20 2006-09-25 주식회사 씨티씨바이오 시부트라민 유리염기 함유 조성물 및 이의 제조방법
US20070203111A1 (en) 2006-01-06 2007-08-30 Sepracor Inc. Cycloalkylamines as monoamine reuptake inhibitors
WO2008034142A2 (en) 2006-09-15 2008-03-20 Reviva Pharmaceuticals, Inc. Synthesis, methods of using, and compositions of cycloalkylmethylamines
US8604244B2 (en) 2010-07-02 2013-12-10 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
KR100812538B1 (ko) * 2006-10-23 2008-03-11 한올제약주식회사 약물 제어방출형 메트포르민-글리메피리드 복합제제
KR20080046601A (ko) * 2006-11-22 2008-05-27 에스케이케미칼주식회사 보관안정성이 우수한 시부트라민 함유 포접복합체
EP2952522B1 (en) 2007-01-31 2019-10-30 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
AU2008232709C1 (en) 2007-03-28 2015-01-15 President And Fellows Of Harvard College Stitched polypeptides
US20110027458A1 (en) 2009-07-02 2011-02-03 Dexcom, Inc. Continuous analyte sensors and methods of making same
KR20170058446A (ko) 2010-08-13 2017-05-26 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
AR088392A1 (es) 2011-10-18 2014-05-28 Aileron Therapeutics Inc Macrociclos peptidomimeticos
RU2642074C2 (ru) 2011-12-30 2018-01-24 Ревива Фармасьютикалс, Инк. Композиции, синтез и способы применения производных фенилциклоалкилметиламина
HK1205454A1 (en) 2012-02-15 2015-12-18 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
CA2862038C (en) 2012-02-15 2021-05-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
BR112015009470A2 (pt) 2012-11-01 2019-12-17 Aileron Therapeutics Inc aminoácidos dissubstituídos e seus métodos de preparação e uso
WO2016049359A1 (en) 2014-09-24 2016-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US10253067B2 (en) 2015-03-20 2019-04-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52768B1 (en) * 1981-04-06 1988-02-17 Boots Co Ltd 1-arylcyclobutylalkylamine compounds useful as therapeutic agents
GB8531071D0 (en) * 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
GB8704777D0 (en) * 1987-02-28 1987-04-01 Boots Co Plc Medical treatment
JP2675573B2 (ja) * 1988-03-31 1997-11-12 科研製薬株式会社 脳機能改善剤
IE61928B1 (en) * 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
WO1995010292A1 (en) 1993-10-14 1995-04-20 Biomedica California, Inc. Diabetes treatment and prophylaxis
US5459164A (en) * 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process

Also Published As

Publication number Publication date
TW580385B (en) 2004-03-21
PL332305A1 (en) 1999-08-30
MY116150A (en) 2003-11-28
HRP970505A2 (en) 1998-08-31
TR199900618T2 (xx) 1999-06-21
CA2266401C (en) 2007-01-30
AU4774097A (en) 1998-04-14
IL128850A0 (en) 2000-01-31
HUP9904026A2 (hu) 2000-05-28
UA64726C2 (uk) 2004-03-15
US20040077730A1 (en) 2004-04-22
NO991358L (no) 1999-03-19
ID18320A (id) 1998-03-26
WO1998011884A1 (en) 1998-03-26
CA2266401A1 (en) 1998-03-26
EP0927028A1 (en) 1999-07-07
ZA978450B (en) 1999-03-19
IL128850A (en) 2003-07-31
NO991358D0 (no) 1999-03-19
AU724488B2 (en) 2000-09-21
CZ93699A3 (cs) 1999-08-11
SK31999A3 (en) 1999-12-10
JP2001503737A (ja) 2001-03-21
BG64473B1 (bg) 2005-04-30
US6174925B1 (en) 2001-01-16
US6617360B1 (en) 2003-09-09
CN1237905A (zh) 1999-12-08
BG103277A (en) 2000-01-31
RU2245709C2 (ru) 2005-02-10
NZ334580A (en) 2000-09-29
GB9619757D0 (en) 1996-11-06
HUP9904026A3 (en) 2000-07-28
KR20000048501A (ko) 2000-07-25

Similar Documents

Publication Publication Date Title
BR9711517A (pt) Processo para reducÆo da resistencia a insulina em seres humanos nos quais a tolerancia a glicose enfraquecida ou o diabetes melito nÆo dependente de insulina nÆo se tenham apresentado da quantidade de insulina requerida diariamente por um ser humano que tenha diabetes melito e da resistencia a insulina em seres humanos para melhoria do peso e o controle do diabetes de pacientes de diabete melito nÆo dependente de insulina e para profilaxia e efeitos prejudiciais de longo prazo causados por alta
Baker et al. Alteration of adenyl dinucleotide metabolism by environmental stress.
BR0205144A (pt) Composição eficaz hipoglicêmica, e, métodos de tratamento do diabete tipo ii, de prevenir o começo do diabete tipo ii clìnico, de reduzir o nìvel de glicose do sangue em um paciente, de aumentar a secreção da insulina de células beta pancreáticas, e de inibir a degradação de carboidratos complexos em monossacarìdeos
BR0308537A (pt) Composto, composição, e métodos para tratar diabetes tipo 2 e hiperuricemia, para modular resistência a insulina e para aliviar hiperlipidemia em um indivìduo e agente de prodroga
ES2069166T3 (es) Ventilador.
BR9510029A (pt) Fungicidas para o controle da doença "take-all" das plantas
BRPI0408021B8 (pt) dispositivo de distribuição de drogas com mecanismo de acionamento e método de fabricar ou montar um dispositivo de distribuição de drogas.
BR9204191A (pt) Composicao de isca e processo para controlar populacoes de besouro diabroticine,e isca
AU4072799A (en) 2,3,5-substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia
DE69311932D1 (de) Therapeutische und Vorbeugungszusammensetzung für hyperglykämie-abhängige Erkrankungen und Gesundheitsnahrung
BR9801048A (pt) Composição e processo de redução da velocidade de cristalização de um pesticida e de controle de uma praga.
BR0206847A (pt) Tratamento do diabete melito
BR9813801A (pt) Composto, composição farmacêutica, e, processos para o tratamento, controle, ou prevenção, em um mamìfero, de diabete mellitus, de hiperglicemia, de hiperlipidemia, de obesidade, de hipercolesterolemia, e, de hipertrigliceridemia.
BR9706054A (pt) Composição para tratamento da pele
MX161726A (es) Composicion substantiva para el cuidado de la piel,que comprende un polidiorganosiloxano
PT95212A (pt) Processo para a preparacao de uma composicao para uso topico para o tratamento da fragilidade capilar, contendo defibrotide
BR9812390A (pt) Fecho de haste corrediça para uma porta do armário, articulada a um corpo de armário de distribuição
NZ332105A (en) Medicaments including human growth hormone for the treatment of type II diabetes and metabolic syndrome
Heldin et al. Desensitisation of cultured glial cells to epidermal growth factor by receptor down-regulation
Mohan et al. Drug induced diabetes mellitus.
AU1855292A (en) Stick composition with sodium chloride and stearyl alcohol
BR8906608A (pt) Composicao para o combate sistemico de ectoparasitas em hospedeiros,processo para a preparacao de compostos,sua aplicacao,medicamento veterinario e processo para o combate sistemico de ectoparasitas em hospedeiros
IT1288620B1 (it) Meccanismo per cerniere di occhiali con rotazione assiale dell'asta ritorno automatico e extra-apertura.
PT785787E (pt) Utilizacao de derivados de 1,5-benzodiazepina para o controlo de esvaziamento gastrico em doentes com diabetes mellitus nao-insulino dependentes
ATE82122T1 (de) Pharmazeutische und/oder diaetetische zusammensetzungen mit gehalt an l-carnitin und l- lysin.

Legal Events

Date Code Title Description
TC Change of name
PC Transfer

Owner name: ABBOTT GMBH (DE)

TC Change of name
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: DESCONHECIDA A PETICAO DE TRANSFERENCIA NO 042393/RJ DE 31/07/2003, POR FALTA DE FUNDAMENTACAO LEGAL.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1954 DE 17/06/2008.